Compare prices and buy PT-141 + Oxytocin Blend from 3 research peptide vendors - also called suppliers or sources. Updated daily.
A two-peptide blend pairing PT-141 (bremelanotide), a melanocortin receptor agonist whose FDA label calls the mechanism behind its approved use unknown, with oxytocin, the posterior pituitary hormone that acts on the oxytocin receptor. The pairing is a market convention rather than a demonstrated pharmacological one, and no controlled human trial has evaluated the combination. No FDA-approved product combines the two, the split between them varies by vendor, and the blend is sold for laboratory research use only.
For research purposes only. Not medical advice.
The PT-141 + Oxytocin blend combines two peptides in one premixed solution: PT-141, the research name for bremelanotide, and oxytocin, the nine-residue hormone of the posterior pituitary. It is a mixture with no CAS number of its own, and no pharmacopeia recognizes it as a substance.
Vendors do not split the bottle the same way. Some list equal masses of the two peptides and others list twice as much PT-141 as oxytocin, so two bottles with the same total can hold different amounts of each. A title reading "Oxytocin Acetate" names a salt form, and whether a stated mass counts the salt or the free peptide is explained on the oxytocin page. A certificate of analysis for a blend should report each component separately.
PT-141 is a melanocortin receptor agonist. Its FDA label calls it nonselective, ranks the pigmentation receptor MC1R first in potency, and states that the mechanism behind its approved use is unknown. The receptor detail and the trial record are on the PT-141 page.
Oxytocin acts on the oxytocin receptor, a G protein-coupled receptor whose classical roles are uterine contraction during labor and milk ejection during lactation.
The pairing is a market convention rather than a pharmacological one. No controlled human trial has evaluated the combination, and ClinicalTrials.gov lists no registered study that gave the two peptides together.
The published link between the two systems is preclinical, and it does not involve adding oxytocin. In prairie voles, Melanotan II promoted partner preference, a laboratory measure of pair bonding, and raised central oxytocin release. An oxytocin receptor blocker given with it prevented the effect (Modi and colleagues, Neuropsychopharmacology, 2015). Its melanocortin agonist is not the one in this bottle, the oxytocin involved was the animals' own, and the study measured bonding behavior, not sexual function.
The listings PeptideScouter indexes for this blend are nasal sprays. The peptides arrive already dissolved, and the vendor's milligram figure is the stated content of the whole bottle.
Neither component has an approved nasal form in the US. Bremelanotide's early clinical program used an intranasal formulation, in healthy men and men with erectile dysfunction (Diamond and colleagues, International Journal of Impotence Research, 2004) and in a Phase 2 study in women with sexual arousal disorder that began in 2006 (NCT00425256). The later dose-finding trial (NCT01382719) and both Phase 3 trials used subcutaneous injection, and Vyleesi is a subcutaneous autoinjector. Its label still reports one drug-interaction study run with an intranasal bremelanotide spray, a formulation that was never approved.
Oxytocin's current US approvals are all injections. A large human literature on intranasal oxytocin exists, much of it on social behavior and much of it statistically underpowered (Walum and colleagues, Biological Psychiatry, 2016). Whether the nasal route delivers oxytocin to the brain is a separate question, covered with that literature on the oxytocin page.
Both components hold current US approvals, and neither approval covers a nasal spray or a combination.
Because each component belongs to an approved drug, neither one's status turns on the 503A bulk-substance nominations that decide most research peptides. Research-grade material sold by peptide vendors was made under neither approval.
PeptideScouter records a blend's size as the combined peptide mass in the container, the convention explained on the CJC-1295 + Ipamorelin page. Here the format matters more than the split. A price per milligram is computed only for vials measured in milligrams, so spray listings show a bottle price, carry no per-milligram figure and never enter the lowest-per-milligram comparisons elsewhere on the site.
Comparing bottles by hand takes each one's split as well as its total. In a bottle holding twice as much PT-141 as oxytocin, a per-milligram figure mostly reflects the PT-141.
Research-grade material sold by the vendors indexed here is offered for laboratory research use only and not for human consumption.
Two peptides premixed in one solution: PT-141, also called bremelanotide, a melanocortin receptor agonist, and oxytocin, the hormone of the posterior pituitary. The vendor's milligram figure is the combined mass of both in the whole bottle, and the split is not standardized. Some vendors list equal masses of the two and others list twice as much PT-141 as oxytocin, so the product description or certificate of analysis has to state each component's amount. The material is offered for laboratory research use only, not for human consumption.
No controlled human trial has evaluated the combination, and ClinicalTrials.gov lists no registered study that gave the two together. Each component has its own human record: bremelanotide in the Phase 3 trials behind its FDA approval, oxytocin in obstetric use and in a large intranasal research literature. The nearest published link between the two systems is a 2015 prairie vole study in which Melanotan II, a close structural relative of bremelanotide, raised the animals' own oxytocin release, and an oxytocin receptor blocker prevented its effect on pair bonding. Pairing the two in one bottle is a market convention rather than a pharmacological one.
No. Bremelanotide is approved as Vyleesi, a subcutaneous injection given by autoinjector. Its developer tested an intranasal formulation in early clinical studies, but the Phase 3 trials and the approved product use subcutaneous injection. Oxytocin's current US approvals, Pitocin and generic oxytocin injections, are all injections for obstetric use. An oxytocin nasal spray, Syntocinon, once held a US approval, which the FDA withdrew effective September 8, 1997. No FDA-approved product combines the two peptides.
PeptideScouter computes a price per milligram only for listings measured in milligrams and sold as a vial. This blend's listings are nasal sprays, premixed solutions sold by the bottle, so they show a bottle price and the combined milligram total but are left out of every per-milligram table and lowest-per-milligram figure on the site. Comparing two bottles by hand also takes each one's split between the two peptides, since the total alone does not say how much of each a bottle holds.
A CAS Registry Number identifies a single chemical substance, and this blend is a mixture of two. Each component has its own: bremelanotide is CAS 189691-06-3 and oxytocin is CAS 50-56-6, with oxytocin acetate, a salt of the same peptide, registered separately under CAS 6233-83-6. A certificate of analysis for the blend should identify and quantify each component separately.
PT-141 + Oxytocin Blend is sold by 3 research peptide vendors indexed on PeptideScouter, with 3 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
All 3 indexed research peptide vendors currently have PT-141 + Oxytocin Blend in stock. Stock state is refreshed daily from each vendor's catalog.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 3 vendors listing PT-141 + Oxytocin Blend publish a PeptideScouter code, worth 10% off. These listings do not carry a comparable per-milligram price, so code availability is shown without a normalized effective price. Each vendor's code is shown beside its price in the table above.
3 research peptide vendors currently list PT-141 + Oxytocin Blend on PeptideScouter. We track 3 listings across size and kit variants.
